Lidia Wydeheft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lidia Wydeheft has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Kornelia Kędziora-Kornatowska
Department of Geriatrics, Faculty of Health Science, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Skłodowska-Curie 9 Street, 85-094 Bydgoszcz, Poland
4 shared publications - Justyna Jusiak
Hospital The Monument of the Baptism of Poland, Gniezno, Poland
3 shared publications - Michał Janiak
Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland
3 shared publications - Paulina Halik
The Baptism of Poland Memorial Hospital, ul. Świętego Jana 9, 62-200 Gniezno, Poland
3 shared publications - Paulina Malon
Nicolaus Copernicus University in Toruń, Collegium Medicum, Bydgoszcz
3 shared publications - Katarzyna Mądra-Gackowska
Department of Geriatrics, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 9 Skłodowskiej Curie Str., 85-094 Bydgoszcz, Poland
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1298
Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence
Background/Objectives: Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics/pharmacodynamics (PK/PD), and clinical outcomes to identify where translation is maintained or lost. Methods: The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. Results: Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65–0.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85–1.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46–5.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18–0.55). Conclusions: Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.
- 17 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1298
Open AccessTranslational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence
Background/Objectives: Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics/pharmacodynamics (PK/PD), and clinical outcomes to identify where translation is maintained or lost. Methods: The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. Results: Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65–0.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85–1.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46–5.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18–0.55). Conclusions: Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.
- Open Access
- 30 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1017
Small-Molecule Factor Xa Inhibitors: Translational SAR, Assay-Aware Data Quality, and QSAR-Readiness for CADD-Oriented Discovery
Factor Xa (FXa) remains a clinically validated and chemically tractable anticoagulant target despite the therapeutic role of direct oral FXa inhibitors. Contemporary FXa inhibitor literature, however, is heterogeneous in scaffold design, endpoint reporting, assay consistency, translational depth, and suitability for computer-aided drug design (CADD). This review evaluates published series of small-molecule FXa inhibitors through a framework that combines translational structure–activity relationships (SARs), assay-aware data quality, and QSAR-readiness. A structured narrative synthesis focused mainly on post-2014 studies reporting discrete small-molecule or semisynthetic FXa inhibitors. Eligible series were classified as fully synthetic or natural-product-derived/semisynthetic chemotypes, and extraction covered scaffold architecture, potency endpoints, assay context, selectivity, clotting or antithrombotic readouts, PK/ADME, structural clarity, translational context, and extraction confidence. QSAR-readiness was assessed using analog density, congenericity, endpoint quality, assay comparability, activity range, structural interpretability, and curation burden. Fully synthetic chemotypes, particularly anthranilamide-derived and related scaffolds, provided the most coherent and modellable FXa datasets, whereas natural-product-derived and semisynthetic series expanded structural diversity. Many exploratory series, however, were limited by small analog sets, heterogeneous endpoints, incomplete translational characterization, narrow activity ranges, or higher curation burden. The practical value of published FXa inhibitor series, therefore, depends not only on potency but also on whether chemical and biological information can be reconstructed with confidence for reproducible SAR interpretation, local QSAR modeling, AI/ML-enabled CADD reuse, and clinical benchmark-aware prioritization. The QSAR-readiness framework is a critical triage tool, not a substitute for formal validation, distinguishing datasets suitable for curated local modeling from those better suited to qualitative SAR, scaffold inspiration, or translational hypotheses.
- 30 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1017
Open AccessSmall-Molecule Factor Xa Inhibitors: Translational SAR, Assay-Aware Data Quality, and QSAR-Readiness for CADD-Oriented Discovery
Factor Xa (FXa) remains a clinically validated and chemically tractable anticoagulant target despite the therapeutic role of direct oral FXa inhibitors. Contemporary FXa inhibitor literature, however, is heterogeneous in scaffold design, endpoint reporting, assay consistency, translational depth, and suitability for computer-aided drug design (CADD). This review evaluates published series of small-molecule FXa inhibitors through a framework that combines translational structure–activity relationships (SARs), assay-aware data quality, and QSAR-readiness. A structured narrative synthesis focused mainly on post-2014 studies reporting discrete small-molecule or semisynthetic FXa inhibitors. Eligible series were classified as fully synthetic or natural-product-derived/semisynthetic chemotypes, and extraction covered scaffold architecture, potency endpoints, assay context, selectivity, clotting or antithrombotic readouts, PK/ADME, structural clarity, translational context, and extraction confidence. QSAR-readiness was assessed using analog density, congenericity, endpoint quality, assay comparability, activity range, structural interpretability, and curation burden. Fully synthetic chemotypes, particularly anthranilamide-derived and related scaffolds, provided the most coherent and modellable FXa datasets, whereas natural-product-derived and semisynthetic series expanded structural diversity. Many exploratory series, however, were limited by small analog sets, heterogeneous endpoints, incomplete translational characterization, narrow activity ranges, or higher curation burden. The practical value of published FXa inhibitor series, therefore, depends not only on potency but also on whether chemical and biological information can be reconstructed with confidence for reproducible SAR interpretation, local QSAR modeling, AI/ML-enabled CADD reuse, and clinical benchmark-aware prioritization. The QSAR-readiness framework is a critical triage tool, not a substitute for formal validation, distinguishing datasets suitable for curated local modeling from those better suited to qualitative SAR, scaffold inspiration, or translational hypotheses.
- Open Access
- 24 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Falls in the Elderly: Determinants, Consequences and Prevention Approaches
Introduction:Falls among older adults are a major global public health problem and a leading cause of injury, disability and mortality in individuals aged 65 years and older. With population aging, the incidence and burden of falls are expected to increase. Falls result from complex interactions between intrinsic age-related changes and extrinsic environmental factors, making them a core geriatric syndrome requiring comprehensive management.Aim:This review aimed to summarize current evidence on the epidemiology, determinants, consequences, and prevention strategies for falls in older adults.Materials and Methods:A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Peer-reviewed articles, meta-analyses, and clinical guidelines published between 2018 and 2025 were included.Results:Approximately one-third of community-dwelling adults aged ≥65 experience at least one fall annually, with higher rates among those aged ≥80 and residents of long-term care facilities. Major risk factors include advanced age, prior falls, gait and balance impairment, muscle weakness, frailty, multimorbidity, polypharmacy, visual and cognitive impairment, and environmental hazards. Falls often lead to fractures, head injuries, functional decline, psychological consequences such as fear of falling, and increased healthcare utilization. Discussion:The findings confirm the multifactorial nature of falls and the cumulative impact of modifiable and non-modifiable risk factors. Psychological consequences, particularly fear of falling, contribute to recurrent falls and progressive functional decline. Conclusions:Falls in older adults represent a complex geriatric syndrome with substantial clinical and socioeconomic consequences. Integrated, multifactorial prevention programs based on comprehensive geriatric assessment are essential to reduce fall risk, maintain independence, and mitigate healthcare system burden.
- 24 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessFalls in the Elderly: Determinants, Consequences and Prevention Approaches
Introduction:Falls among older adults are a major global public health problem and a leading cause of injury, disability and mortality in individuals aged 65 years and older. With population aging, the incidence and burden of falls are expected to increase. Falls result from complex interactions between intrinsic age-related changes and extrinsic environmental factors, making them a core geriatric syndrome requiring comprehensive management.Aim:This review aimed to summarize current evidence on the epidemiology, determinants, consequences, and prevention strategies for falls in older adults.Materials and Methods:A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Peer-reviewed articles, meta-analyses, and clinical guidelines published between 2018 and 2025 were included.Results:Approximately one-third of community-dwelling adults aged ≥65 experience at least one fall annually, with higher rates among those aged ≥80 and residents of long-term care facilities. Major risk factors include advanced age, prior falls, gait and balance impairment, muscle weakness, frailty, multimorbidity, polypharmacy, visual and cognitive impairment, and environmental hazards. Falls often lead to fractures, head injuries, functional decline, psychological consequences such as fear of falling, and increased healthcare utilization. Discussion:The findings confirm the multifactorial nature of falls and the cumulative impact of modifiable and non-modifiable risk factors. Psychological consequences, particularly fear of falling, contribute to recurrent falls and progressive functional decline. Conclusions:Falls in older adults represent a complex geriatric syndrome with substantial clinical and socioeconomic consequences. Integrated, multifactorial prevention programs based on comprehensive geriatric assessment are essential to reduce fall risk, maintain independence, and mitigate healthcare system burden.
- Open Access
- 10 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67673
GLP-1 Agonists and Dual Agonists in Obesity Treatment: Benefits, Risks, and Clinical Challenges in Geriatric Patients
Introduction. The global prevalence of obesity has increased markedly in recent decades, becoming a major contributor to metabolic syndrome (MetS), cardiovascular disease, and mortality. This trend increasingly affects older adults, in whom obesity often coexists with sarcopenia, frailty, and multimorbidity. Novel pharmacological therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have demonstrated unprecedented efficacy in weight reduction, yet data in geriatric populations remain limited. Materials and Methods. A systematic literature search of PubMed, Embase, and Scopus was conducted for studies published between 2020 and 2025. Results. Both semaglutide and tirzepatide produced substantial and sustained weight loss, with mean reductions ranging from approximately 15% to over 20%, and significant improvements in glycemic control, lipid profile, and blood pressure. Tirzepatide consistently achieved greater weight reduction than semaglutide. Limited subgroup and post hoc analyses suggest that older adults experience meaningful metabolic benefits, although higher rates of gastrointestinal adverse events and treatment discontinuation have been reported. Discussion. In older patients, pharmacologically induced weight loss may be accompanied by disproportionate loss of lean body mass, increasing the risk of sarcopenia, frailty, and functional decline. Without appropriate nutritional and exercise interventions, these risks may attenuate the cardiometabolic benefits of treatment. Conclusions. GLP-1 and dual GLP-1/GIP receptor agonists are highly effective therapies for obesity, including in older adults, but require individualized risk–benefit assessment. Integration with nutritional support and resistance training is essential.
- 10 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67673
Open AccessGLP-1 Agonists and Dual Agonists in Obesity Treatment: Benefits, Risks, and Clinical Challenges in Geriatric Patients
Introduction. The global prevalence of obesity has increased markedly in recent decades, becoming a major contributor to metabolic syndrome (MetS), cardiovascular disease, and mortality. This trend increasingly affects older adults, in whom obesity often coexists with sarcopenia, frailty, and multimorbidity. Novel pharmacological therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have demonstrated unprecedented efficacy in weight reduction, yet data in geriatric populations remain limited. Materials and Methods. A systematic literature search of PubMed, Embase, and Scopus was conducted for studies published between 2020 and 2025. Results. Both semaglutide and tirzepatide produced substantial and sustained weight loss, with mean reductions ranging from approximately 15% to over 20%, and significant improvements in glycemic control, lipid profile, and blood pressure. Tirzepatide consistently achieved greater weight reduction than semaglutide. Limited subgroup and post hoc analyses suggest that older adults experience meaningful metabolic benefits, although higher rates of gastrointestinal adverse events and treatment discontinuation have been reported. Discussion. In older patients, pharmacologically induced weight loss may be accompanied by disproportionate loss of lean body mass, increasing the risk of sarcopenia, frailty, and functional decline. Without appropriate nutritional and exercise interventions, these risks may attenuate the cardiometabolic benefits of treatment. Conclusions. GLP-1 and dual GLP-1/GIP receptor agonists are highly effective therapies for obesity, including in older adults, but require individualized risk–benefit assessment. Integration with nutritional support and resistance training is essential.
- Open Access
- 31 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Providing general anesthesia for elderly patients during planned procedures — main differences compared to younger adults
IntroductionThe aging population has increased the number of older adults undergoing elective surgery, making safe, individualized general anesthesia essential. Age-related physiological changes—such as reduced cardiac, pulmonary, hepatic, and renal reserve, multimorbidity, frailty, and altered body composition—affect drug metabolism, pharmacodynamics, and tolerance to perioperative stress, resulting in higher rates of cardiovascular, respiratory, and cognitive complications compared with younger adults.ResultsOlder patients require careful dose adjustments due to reduced drug clearance and increased sensitivity to anesthetics. Propofol-based total intravenous anesthesia (TIVA), EEG-guided depth monitoring, and agents like etomidate or dexmedetomidine improve hemodynamic stability and reduce postoperative cognitive dysfunction (POCD) and delirium. Comprehensive preoperative evaluation—including frailty screening, cognitive and functional assessment, and medication review—helps identify high-risk patients. Postoperative vigilance is needed to manage respiratory depression, inadequate pain control, and prolonged recovery. Telemedicine has proven effective for pre-anesthetic assessment, enabling early detection of cognitive impairment and reducing time, cost, and travel burden.DiscussionPersonalized anesthesia considering frailty, comorbidities, and altered drug metabolism improves safety. Minimizing anesthetic duration, selecting safer agents, EEG guidance, and TIVA support better outcomes, while telemedicine enhances patient-centered care.ConclusionGeneral anesthesia in older adults requires tailored strategies addressing age-related changes and increased perioperative vulnerability. Individualized dosing, careful agent selection, structured preoperative assessment, postoperative monitoring, and telemedicine support can enhance safety and outcomes, highlighting key differences from younger patients and emphasizing a holistic, evidence-based perioperative approach.
- 31 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Open AccessProviding general anesthesia for elderly patients during planned procedures — main differences compared to younger adults
IntroductionThe aging population has increased the number of older adults undergoing elective surgery, making safe, individualized general anesthesia essential. Age-related physiological changes—such as reduced cardiac, pulmonary, hepatic, and renal reserve, multimorbidity, frailty, and altered body composition—affect drug metabolism, pharmacodynamics, and tolerance to perioperative stress, resulting in higher rates of cardiovascular, respiratory, and cognitive complications compared with younger adults.ResultsOlder patients require careful dose adjustments due to reduced drug clearance and increased sensitivity to anesthetics. Propofol-based total intravenous anesthesia (TIVA), EEG-guided depth monitoring, and agents like etomidate or dexmedetomidine improve hemodynamic stability and reduce postoperative cognitive dysfunction (POCD) and delirium. Comprehensive preoperative evaluation—including frailty screening, cognitive and functional assessment, and medication review—helps identify high-risk patients. Postoperative vigilance is needed to manage respiratory depression, inadequate pain control, and prolonged recovery. Telemedicine has proven effective for pre-anesthetic assessment, enabling early detection of cognitive impairment and reducing time, cost, and travel burden.DiscussionPersonalized anesthesia considering frailty, comorbidities, and altered drug metabolism improves safety. Minimizing anesthetic duration, selecting safer agents, EEG guidance, and TIVA support better outcomes, while telemedicine enhances patient-centered care.ConclusionGeneral anesthesia in older adults requires tailored strategies addressing age-related changes and increased perioperative vulnerability. Individualized dosing, careful agent selection, structured preoperative assessment, postoperative monitoring, and telemedicine support can enhance safety and outcomes, highlighting key differences from younger patients and emphasizing a holistic, evidence-based perioperative approach.
- Open Access
- 28 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 68, 55416
Bempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
Cardiovascular disease remains one of the leading causes of mortality worldwide, with elevated LDL cholesterol being a critical risk factor. Statins have long been the cornerstone of lipid-lowering therapy, but many patients fail to reach target LDL cholesterol levels due to statin intolerance or insufficient response, even when combined with ezetimibe. Recently, the lipid-lowering drug class has been expanded with the introduction of bempedoic acid, a novel agent that inhibits ATP-citrate lyase. Recent studies have demonstrated the efficacy and safety of bempedoic acid in reducing LDL cholesterol levels in patients with hypercholesterolemia, paving the way for its inclusion in clinical guidelines. This article provides a comprehensive overview of the latest evidence regarding bempedoic acid and its emerging role in lipid management. Despite the widespread use of statins, many patients fail to achieve target LDL-C levels due to statin intolerance or insufficient response. This comprehensive review explores the emerging role of bempedoic acid, a novel lipid-lowering agent that inhibits ATP-citrate lyase, in the management of dyslipidemia and cardiovascular risk reduction. Bempedoic acid, approved by the FDA in 2020, offers a unique mechanism of action that complements existing therapies. As a prodrug activated specifically in the liver, it avoids muscle-related side effects commonly associated with statins. Clinical trials have demonstrated its efficacy in reducing LDL-C levels, particularly in patients with statin intolerance or those requiring additional LDL-C lowering beyond maximally tolerated statin therapy. The review synthesizes data from multiple phase 3 clinical trials, including CLEAR Wisdom and CLEAR Outcomes, which have shown significant LDL-C reductions with bempedoic acid monotherapy and in combination with other lipid-lowering agents. Notably, bempedoic acid not only lowers LDL-C but also reduces high-sensitivity C-reactive protein (hs-CRP) levels, suggesting potential anti-inflammatory effects. Safety profiles from these trials indicate that bempedoic acid is generally well-tolerated, with minimal muscle-related adverse events. However, slight increases in serum creatinine and uric acid levels have been observed, warranting monitoring in certain patient populations. Recent updates to clinical guidelines, including the 2024 European Society of Cardiology guidelines on coronary heart disease, now recommend bempedoic acid for specific patient groups. These include statin-intolerant patients not achieving LDL-C goals on ezetimibe alone, and those not reaching targets on maximum tolerated statin doses combined with ezetimibe. This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with statin intolerance or requiring additional LDL-C reduction. As research continues, bempedoic acid's role in reducing cardiovascular events and its long-term safety profile will be further elucidated, potentially reshaping the landscape of dyslipidemia management and cardiovascular risk reduction.
- 28 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 68, 55416
Open AccessBempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
Cardiovascular disease remains one of the leading causes of mortality worldwide, with elevated LDL cholesterol being a critical risk factor. Statins have long been the cornerstone of lipid-lowering therapy, but many patients fail to reach target LDL cholesterol levels due to statin intolerance or insufficient response, even when combined with ezetimibe. Recently, the lipid-lowering drug class has been expanded with the introduction of bempedoic acid, a novel agent that inhibits ATP-citrate lyase. Recent studies have demonstrated the efficacy and safety of bempedoic acid in reducing LDL cholesterol levels in patients with hypercholesterolemia, paving the way for its inclusion in clinical guidelines. This article provides a comprehensive overview of the latest evidence regarding bempedoic acid and its emerging role in lipid management. Despite the widespread use of statins, many patients fail to achieve target LDL-C levels due to statin intolerance or insufficient response. This comprehensive review explores the emerging role of bempedoic acid, a novel lipid-lowering agent that inhibits ATP-citrate lyase, in the management of dyslipidemia and cardiovascular risk reduction. Bempedoic acid, approved by the FDA in 2020, offers a unique mechanism of action that complements existing therapies. As a prodrug activated specifically in the liver, it avoids muscle-related side effects commonly associated with statins. Clinical trials have demonstrated its efficacy in reducing LDL-C levels, particularly in patients with statin intolerance or those requiring additional LDL-C lowering beyond maximally tolerated statin therapy. The review synthesizes data from multiple phase 3 clinical trials, including CLEAR Wisdom and CLEAR Outcomes, which have shown significant LDL-C reductions with bempedoic acid monotherapy and in combination with other lipid-lowering agents. Notably, bempedoic acid not only lowers LDL-C but also reduces high-sensitivity C-reactive protein (hs-CRP) levels, suggesting potential anti-inflammatory effects. Safety profiles from these trials indicate that bempedoic acid is generally well-tolerated, with minimal muscle-related adverse events. However, slight increases in serum creatinine and uric acid levels have been observed, warranting monitoring in certain patient populations. Recent updates to clinical guidelines, including the 2024 European Society of Cardiology guidelines on coronary heart disease, now recommend bempedoic acid for specific patient groups. These include statin-intolerant patients not achieving LDL-C goals on ezetimibe alone, and those not reaching targets on maximum tolerated statin doses combined with ezetimibe. This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with statin intolerance or requiring additional LDL-C reduction. As research continues, bempedoic acid's role in reducing cardiovascular events and its long-term safety profile will be further elucidated, potentially reshaping the landscape of dyslipidemia management and cardiovascular risk reduction.
- Open Access
- 15 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (4) , 3439
Outcomes of Transcatheter Aortic Valve Implantation Comparing Medtronic’s Evolut PRO and Evolut R: A Systematic Review and Meta-Analysis of Observational Studies
Background: Transcatheter aortic valve implantation (TAVI) has become a broadly acceptable alternative to AV surgery in patients with aortic stenosis (AS). New valve designs are becoming available to address the shortcomings of their predecessors and improve clinical outcomes. Methods: A systematic review and meta-analysis was carried out to compare Medtronic’s Evolut PRO, a new valve, with the previous Evolut R design. Procedural, functional and clinical endpoints according to the VARC-2 criteria were assessed. Results: Eleven observational studies involving N = 12,363 patients were included. Evolut PRO patients differed regarding age (p < 0.001), sex (p < 0.001) and STS–PROM estimated risk. There was no difference between the two devices in terms of TAVI-related early complications and clinical endpoints. A 35% reduction of the risk of moderate-to-severe paravalvular leak (PVL) favoring the Evolut PRO was observed (RR 0.66, 95%CI, [0.52, 0.86] p = 0.002; I2 = 0%). Similarly, Evolut PRO-treated patients demonstrated a reduction of over 35% in the risk of serious bleeding as compared with the Evolut R (RR 0.63, 95%CI, [0.41, 0.96]; p = 0.03; I2 = 39%), without differences in major vascular complications. Conclusions: The evidence shows good short-term outcomes of both the Evolut PRO and Evolut R prostheses, with no differences in clinical and procedural endpoints. The Evolut PRO was associated with a lower rate of moderate-to-severe PVL and major bleeding.
- 15 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (4) , 3439
Open AccessOutcomes of Transcatheter Aortic Valve Implantation Comparing Medtronic’s Evolut PRO and Evolut R: A Systematic Review and Meta-Analysis of Observational Studies
Background: Transcatheter aortic valve implantation (TAVI) has become a broadly acceptable alternative to AV surgery in patients with aortic stenosis (AS). New valve designs are becoming available to address the shortcomings of their predecessors and improve clinical outcomes. Methods: A systematic review and meta-analysis was carried out to compare Medtronic’s Evolut PRO, a new valve, with the previous Evolut R design. Procedural, functional and clinical endpoints according to the VARC-2 criteria were assessed. Results: Eleven observational studies involving N = 12,363 patients were included. Evolut PRO patients differed regarding age (p < 0.001), sex (p < 0.001) and STS–PROM estimated risk. There was no difference between the two devices in terms of TAVI-related early complications and clinical endpoints. A 35% reduction of the risk of moderate-to-severe paravalvular leak (PVL) favoring the Evolut PRO was observed (RR 0.66, 95%CI, [0.52, 0.86] p = 0.002; I2 = 0%). Similarly, Evolut PRO-treated patients demonstrated a reduction of over 35% in the risk of serious bleeding as compared with the Evolut R (RR 0.63, 95%CI, [0.41, 0.96]; p = 0.03; I2 = 39%), without differences in major vascular complications. Conclusions: The evidence shows good short-term outcomes of both the Evolut PRO and Evolut R prostheses, with no differences in clinical and procedural endpoints. The Evolut PRO was associated with a lower rate of moderate-to-severe PVL and major bleeding.
- Open Access
- 26 April 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (6) , 39-50
The effect of obstructive sleep apnea on the cardiovascular system
Introduction: Obstructive Sleep Apnea is a disease entity that affects many aspects of life, but is often overlooked and underdiagnosed. OSA is defined as episodes of apnea-hypopnea that disturbs not only sleep, but also daytime functioning. Symptoms can be divided into night symptoms (not breathing, snoring, gasping, fragmented sleep) and daytime symptoms (fatigue, low concentration, morning headaches, decreased libido). Moreover, OSA through many mechanisms affects the cardiovascular system and leads to its dysfunction. Purpose: The aim of this study is to draw attention to the often underdiagnosed disease entity, which is OSA, which, if left untreated, may lead to serious complications. Material and methods: In 2022, the PubMed and Google Scholar databases were searched using the following keywords: OSA, apnea, cardiovascular disorders, arrhythmias and heart disease. Works in English with the most recent data have been selected. Summary: OSA is strongly associated with cardiovascular disorders, moreover, in both cases, we find similar risk factors for these disorders. A correlation has been demonstrated between OSA and atrial fibrillation, hypertension, and arrhythmias. On the other hand, OSA is still underdiagnosed and more research is needed to understand the correlation between these diseases.
- 26 April 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (6) , 39-50
Open AccessThe effect of obstructive sleep apnea on the cardiovascular system
Introduction: Obstructive Sleep Apnea is a disease entity that affects many aspects of life, but is often overlooked and underdiagnosed. OSA is defined as episodes of apnea-hypopnea that disturbs not only sleep, but also daytime functioning. Symptoms can be divided into night symptoms (not breathing, snoring, gasping, fragmented sleep) and daytime symptoms (fatigue, low concentration, morning headaches, decreased libido). Moreover, OSA through many mechanisms affects the cardiovascular system and leads to its dysfunction. Purpose: The aim of this study is to draw attention to the often underdiagnosed disease entity, which is OSA, which, if left untreated, may lead to serious complications. Material and methods: In 2022, the PubMed and Google Scholar databases were searched using the following keywords: OSA, apnea, cardiovascular disorders, arrhythmias and heart disease. Works in English with the most recent data have been selected. Summary: OSA is strongly associated with cardiovascular disorders, moreover, in both cases, we find similar risk factors for these disorders. A correlation has been demonstrated between OSA and atrial fibrillation, hypertension, and arrhythmias. On the other hand, OSA is still underdiagnosed and more research is needed to understand the correlation between these diseases.